Cerus Corp
NASDAQ:CERS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cerus Corp
NASDAQ:CERS
|
US |
|
Wulff Yhtiot Oyj
LSE:0IU9
|
FI |
|
N
|
Newriver Reit PLC
OTC:NRWRF
|
UK |
|
N
|
Nike Inc
XHAN:NKE
|
US |
Cerus Corp
Cerus Corp makes blood safety products that are used to treat donated blood before it goes to patients. Its main product is the INTERCEPT Blood System, which uses a chemical and light process to reduce the risk that viruses, bacteria, and other harmful pathogens in platelets, plasma, and some red blood cell products can be passed through transfusion. In simple terms, Cerus sells equipment and single-use treatment kits that help blood centers make donated blood safer. The company’s main customers are blood banks, blood centers, and hospitals that collect, process, and transfuse blood. Cerus makes money by selling the INTERCEPT devices and the disposable treatment sets that must be used with them, along with related support and service. Because the kits are used up with each batch of blood, the business depends on repeat purchases rather than one-time equipment sales alone. Cerus sits in a niche part of the healthcare supply chain. It does not collect or transfuse blood itself; instead, it provides the safety step that happens before blood products reach patients. That makes its role different from most medical device companies, because its products are tied directly to blood processing and transfusion safety rather than to a broad range of hospital procedures.
Cerus Corp makes blood safety products that are used to treat donated blood before it goes to patients. Its main product is the INTERCEPT Blood System, which uses a chemical and light process to reduce the risk that viruses, bacteria, and other harmful pathogens in platelets, plasma, and some red blood cell products can be passed through transfusion. In simple terms, Cerus sells equipment and single-use treatment kits that help blood centers make donated blood safer.
The company’s main customers are blood banks, blood centers, and hospitals that collect, process, and transfuse blood. Cerus makes money by selling the INTERCEPT devices and the disposable treatment sets that must be used with them, along with related support and service. Because the kits are used up with each batch of blood, the business depends on repeat purchases rather than one-time equipment sales alone.
Cerus sits in a niche part of the healthcare supply chain. It does not collect or transfuse blood itself; instead, it provides the safety step that happens before blood products reach patients. That makes its role different from most medical device companies, because its products are tied directly to blood processing and transfusion safety rather than to a broad range of hospital procedures.
Revenue: Cerus posted second-quarter product revenue of $57.4 million, up 10% year over year, and said demand remained strong across product categories.
Guidance: Management raised full-year 2026 product revenue guidance to $229 million to $231 million and lifted IFC revenue guidance to $23 million to $25 million.
IFC Growth: U.S. IFC revenue reached $6.7 million, and management said kit adoption, BCA partnerships, and hospital activations are driving momentum.
Margins: Product gross margin was 51.4%, pressured by a stronger euro and inflation, but management still expects 2026 gross margins to stay in the low 50s.
Pipeline: Cerus submitted the INT200 platelet PMA to the FDA and remains on track for top-line RedeS red blood cell data in the fourth quarter.
Balance Sheet: A debt refinancing reduced term debt by $30 million and is expected to cut annual interest expense by up to $3.5 million.
